MRZM Projected Dividend Yield
Marizyme Inc ( OTCBB : MRZM )Marizyme is focusing on the life sciences business. Co. has four product candidates derived from the protease enzyme platform. The first product candidate is MB101 which is targeted to be used to debride and heal human wounds. MB101 is a clinical stage candidate. The second product candidate is MB102 which is targeted for acute cerebral ischemic stroke in pediatric patients. MB102 is in preclinical stage of development. MB103 is Co.'s third product candidate and is in preclinical development. It is targeted to treat acute myocardial infarction in human adults. The fourth product candidate is MB104 which is targeted to treat deep vein thrombosis. It is in early preclinical development. 20 YEAR PERFORMANCE RESULTS |
MRZM Dividend History Detail MRZM Dividend News MRZM Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |